Astrazeneca plc ADR (NASDAQ:AZN) shares, rose in value, with the stock price down by -0.82% to the previous day’s close as strong demand from buyers drove the stock to $70.38.
Actively observing the price movement in the last trading, the stock closed the session at $70.96. The PE ratio was 28.27 over 12-month period. Referring to stock’s 52-week performance, its high was $87.68, and the low was $61.24. On the whole, AZN has fluctuated by 0.64% over the past month.
With the market capitalization of Astrazeneca plc ADR currently standing at about $218.27 billion, investors are eagerly awaiting this quarter’s results, scheduled for in June. The company’s Forward Dividend Ratio is 1.55, with its dividend yield at 2.20%.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AZN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 2.53, with the price of AZN currently trading nearly 1.07% and 0.32% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.08, while the 7-day volatility ratio is showing 0.73% which for the 30-day chart, stands at 1.75%. Furthermore, Astrazeneca plc ADR (AZN)’s beta value is 0.38, and its average true range (ATR) is 1.44.
A comparison of Astrazeneca plc ADR (AZN) with its peers suggests the former has fared considerably weaker in the market. AZN showed an intraday change of -0.82% in last session, and over the past year, it shrunk by -9.98%%.
Data on historical trading for Astrazeneca plc ADR (NASDAQ:AZN) indicates that the trading volumes over the past 3 months, they’ve averaged 5.90 million. According to company’s latest data on outstanding shares, there are 3.10 billion shares outstanding.
Nearly 0.01% of Astrazeneca plc ADR’s shares belong to company insiders and institutional investors own 16.54% of the company’s shares. The stock has risen by 7.42% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AZN stock heading into the next quarter.
